---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-018937"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2021-08-06T23:59:59+00:00"
generated_at: "2026-06-29T21:01:16.819253+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Indaptus Therapeutics completes reverse merger with Decoy Biosystems; begins trading as INDP on Nasdaq

## Summary
- Decoy merger closed Aug 3, 2021; exchange ratio of 2.654353395 Indaptus shares per Decoy share.
- Post-merger 5,405,963 shares outstanding; Decoy shareholders own 65.6%, Intec Israel owns 34.4%.
- Company renamed Indaptus Therapeutics, now a pre-clinical biotech focused on cancer and viral immunotherapy.
- Board expanded to eight directors; Michael Newman appointed Chief Scientific Officer; CEO Meckler remains.
- Expected to dismiss PWC as auditor and engage Haskell & White for fiscal 2021 audit.

## SEC filing metadata
- accession: 0001493152-21-018937
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2021-08-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 3.01, 3.02, 8.01, 4.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/0001493152-21-018937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-018937
- JSON: https://secwatch.observer/filing/0001493152-21-018937.json
- Plain text: https://secwatch.observer/filing/0001493152-21-018937.txt

## Key facts
- Executive change
  Brian O’Callaghan was appointed as Director at Indaptus Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/0001493152-21-018937-index.htm
- Executive change
  Michael Newman was appointed as Chief Scientific Officer at Indaptus Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Scientific Officer
  source text: Michael Newman, Ph.D. was appointed as Chief Scientific Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/0001493152-21-018937-index.htm
- Executive change
  Hoonmo Lee was appointed as Director at Indaptus Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/0001493152-21-018937-index.htm
- Executive change
  Michael Newman was appointed as Director at Indaptus Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: each of Michael Newman, Ph.D., Hoonmo Lee and Brian O’Callaghan were appointed as directors of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/0001493152-21-018937-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.